Compare Novo Nordisk A/S (NVO) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Novo Nordisk A/S trades at $38.4 (market cap $165.31B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $66.76 (market cap $7.43B). The key difference: Novo Nordisk A/S is far larger — about 22.2× Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 0 Days on average.
| NVO | VIST | |
|---|---|---|
Market Cap | $165.31B | $7.43B |
Volume | 11,432,838 | 875,552 |
Sector | Health | Energy |
52-Week High | $63.98 | $79.25 |
52-Week Low | $35.29 | $35.02 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $179.56B | $10.58B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
